QTRX Quote, Financials, Valuation and Earnings

Hologic has a net margin of -34.09% compared to Quanterix's net margin of 19.67%. Quanterix's return on equity of -11.35% beat Hologic's return on equity of 15.28%.

Quanterix has a consensus price target of $14.50, signalling upside risk potential of 115.77%. On the other hand Hologic has an analysts' consensus of $78.15 which suggests that it could grow by 29.05%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Quanterix has a beta of 1.351, which suggesting that the stock is 35.098% more volatile than S&P 500. In comparison Hologic has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.493%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than Hologic quarterly revenues of $1B. Quanterix's net income of -$11.6M is lower than Hologic's net income of $201M. Notably, Quanterix's price-to-earnings ratio is -- while Hologic's PE ratio is 19.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.90x versus 3.53x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis has a net margin of -34.09% compared to Quanterix's net margin of -63.22%. Quanterix's return on equity of -11.35% beat Nuwellis's return on equity of -800.59%.

Quanterix has a consensus price target of $14.50, signalling upside risk potential of 115.77%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1200%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Quanterix has a beta of 1.351, which suggesting that the stock is 35.098% more volatile than S&P 500. In comparison Nuwellis has a beta of 0.510, suggesting its less volatile than the S&P 500 by 49.013%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are larger than Nuwellis quarterly revenues of $2.3M. Quanterix's net income of -$11.6M is lower than Nuwellis's net income of -$1.5M. Notably, Quanterix's price-to-earnings ratio is -- while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.90x versus 0.18x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -34.09% compared to Quanterix's net margin of 5.64%. Quanterix's return on equity of -11.35% beat TransMedics Group's return on equity of 19.17%.

Quanterix has a consensus price target of $14.50, signalling upside risk potential of 115.77%. On the other hand TransMedics Group has an analysts' consensus of $102.86 which suggests that it could grow by 40.69%. Given that Quanterix has higher upside potential than TransMedics Group, analysts believe Quanterix is more attractive than TransMedics Group.

Quanterix has a beta of 1.351, which suggesting that the stock is 35.098% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.138, suggesting its more volatile than the S&P 500 by 113.849%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than TransMedics Group quarterly revenues of $121.6M. Quanterix's net income of -$11.6M is lower than TransMedics Group's net income of $6.9M. Notably, Quanterix's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 72.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.90x versus 5.83x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -34.09% compared to Quanterix's net margin of -0.15%. Quanterix's return on equity of -11.35% beat Varex Imaging's return on equity of -8.27%.

Quanterix has a consensus price target of $14.50, signalling upside risk potential of 115.77%. On the other hand Varex Imaging has an analysts' consensus of $21.20 which suggests that it could grow by 85.48%. Given that Quanterix has higher upside potential than Varex Imaging, analysts believe Quanterix is more attractive than Varex Imaging.

Quanterix has a beta of 1.351, which suggesting that the stock is 35.098% more volatile than S&P 500. In comparison Varex Imaging has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.121%.

Quanterix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quanterix pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Quanterix quarterly revenues are $34.1M, which are smaller than Varex Imaging quarterly revenues of $199.8M. Quanterix's net income of -$11.6M is lower than Varex Imaging's net income of -$300K. Notably, Quanterix's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quanterix is 1.90x versus 0.57x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.